Complexity in KSR function revealed by Raf inhibitor and KSR structure studies

Small GTPases

Volumn 2, Issue 5, 2011, Pages

  Mckay, Melissa M ^a   Freeman, Alyson K ^a   Morrison, Deborah K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B Raf; C Raf; ERK cascade; KSR; MEK; Raf inhibitors; Ras

Indexed keywords

B RAF KINASE; KINASE SUPPRESSOR OF RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN INHIBITOR; PROTEIN KINASE; RAF INHIBITOR; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

BINDING COMPETITION; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME REGULATION; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 80054687116     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.2.5.17740     Document Type: Review

References (26)

1. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007; 26:3113-3121. PMID:17496910; http://dx.doi.org/10.1038/sj.onc.1210394.
2. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 2007; 1773:1213-1226.
3. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-3310. PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422.
4. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308. PMID:17384584; http://dx.doi.org/10.1038/nrc2109.
5. Rubin GM, Chang HC, Karim F, Laverty T, Michaud NR, Morrison DK, et al. Signal transduction downstream from Ras in Drosophila. Cold Spring Harb Symp Quant Biol 1997; 62:347-352. PMID:9598368.
6. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM. KSR, a novel protein kinase required for RAS signal transduction. Cell 1995; 83:879-888. PMID:8521512; http://dx.doi.org/10.1016/0092-8674(95)90204-X.
7. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298:1912-1934. PMID:12471243; http://dx.doi.org/10.1126/science.1075762.
8. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 2003; 19:91-118. PMID:14570565; http://dx.doi.org/10.1146/annurev.cellbio.19.111401.091942.
9. Müller J, Ory S, Copeland T, Piwnica-Worms H, Morrison DK. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell 2001; 8:983-993. PMID:11741534; http://dx.doi.org/10.1016/S1097-2765(01)00383-5.
10. Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006; 16:443-452. PMID:16879967; http://dx.doi.org/10.1016/j.tcb.2006.07.003.
11. Zeqiraj E, van Aalten DM. Pseudokinases-remnants of evolution or key allosteric regulators? Curr Opin Struct Biol 2010; 20:772-781. PMID:21074407; http://dx.doi.org/10.1016/j.sbi.2010.10.001.
12. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011; 472:366-369. PMID:21441910; http://dx.doi.org/10.1038/nature09860.
13. McKay MM, Ritt DA, Morrison DK. RAF Inhibitor- Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling. Curr Biol 2011; 21:563-568. PMID:21458265; http://dx.doi.org/10.1016/j.cub.2011.02.033.
14. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009; 461:542-545. PMID:19727074; http://dx.doi.org/10.1038/nature08314.
15. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867. PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6.
16. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954. PMID:12068308; http://dx.doi.org/10.1038/nature00766.
17. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. [ix.]. Hematol Oncol Clin North Am 2009; 23:529-545. PMID:19464601; http://dx.doi.org/10.1016/j.hoc.2009.04.001.
18. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, et al. Emerging Raf inhibitors. Expert Opin Emerg Drugs 2009; 14:633-648. PMID:19715444; http://dx.doi.org/10.1517/14728210903232633.
19. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431-435. PMID:20130576; http://dx.doi.org/10.1038/nature08833.
20. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209-221. PMID:20141835; http://dx.doi.org/10.1016/j.cell.2009.12.040.
21. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimmers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427-430. PMID:20179705; http://dx.doi.org/10.1038/nature08902.
22. Rushworth LK, Hindley AD, O'Neill E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 2006; 26:2262-2272. PMID:16508002; http://dx.doi.org/10.1128/MCB.26.6.2262-72.2006.
23. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20:963-969. PMID:16364920; http://dx.doi.org/10.1016/j.molcel.2005.10.022.
24. Hu J, Yu H, Kornev AP, Zhao J, Filbert EL, Taylor SS, et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc Natl Acad Sci USA 2011; 108:6067-6072. PMID:21441104; http://dx.doi.org/10.1073/pnas.1102554108.
25. McKay MM, Ritt DA, Morrison DK. Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci USA 2009; 106:11022-11027. PMID:19541618; http://dx.doi.org/10.1073/pnas.0901590106.
26. Zhou M, Horita DA, Waugh DS, Byrd RA, Morrison DK. Solution structure and functional analysis of the cysteine-rich C1 domain of kinase suppressor of Ras (KSR). J Mol Biol 2002; 315:435-446. PMID:11786023; http://dx.doi.org/10.1006/jmbi.2001.5263.